Combination therapy before surgery for rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of treatments for locally advanced rectal cancer. It uses radiation, chemotherapy, and a drug called AK104 before surgery, and the goal is to see if it can improve results for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have stage II or III rectal cancer that has not spread to other parts of the body.
- Your cancer must be the type called adenocarcinoma.
- You must be in good overall health (able to do daily activities) and have normal blood counts and organ function.
- You must not have had radiation or immunotherapy before.
- You must not have severe autoimmune diseases or other serious health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination for rectal cancer that hasn't spread far: a short course of radiation followed by two drugs (AK112 and CAPOX). The goal is to shrink the tumor before surgery and possibly avoid more aggressive treatments.
This study tests a combination of chemotherapy, radiation, and an immunotherapy drug (called anti-PD-1) before surgery for rectal cancer that has not spread. The goal is to see if this approach can shrink or eliminate the tumor, potentially improving outcomes.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
This trial tests a new combination of treatments (radiation, immunotherapy, and two chemotherapy drugs) given before surgery for people with a specific type of locally advanced rectal cancer that is close to the anus. The goal is to see if this approach is safe and effective.
This trial tests a combination of radiation, chemotherapy, and two immunotherapy drugs (sintilimab and suvemcitug) to see if it can improve outcomes for patients with locally advanced rectal cancer that has not spread. The goal is to shrink the tumor before surgery, potentially making it easier to remove and reducing the risk of recurrence.
This trial tests a combination of chemotherapy and an immunotherapy drug (a PD-1 inhibitor) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can improve outcomes compared to standard treatment.
Hear when a new Locally Advanced Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.